@article {Navarro-Trivi{\~n}oejhpharm-2020-002418, author = {Francisco J Navarro-Trivi{\~n}o and Jose Maria Llamas-Molina and Angela Ayen-Rodriguez and Barbara Cancela-D{\'\i}ez and Ricardo Ruiz-Villaverde}, title = {Dramatic improvement of bullous pemphigoid with omalizumab in an elderly patient}, elocation-id = {ejhpharm-2020-002418}, year = {2020}, doi = {10.1136/ejhpharm-2020-002418}, publisher = {BMJ Specialist Journals}, abstract = {A 70-year-old man with a history of hypertension was evaluated in our dermatology department due to the appearance of a clinical picture compatible with bullous pemphigoid that was confirmed histologically. The lack of response to topical and systemic immunosuppressive treatment resulted in omalizumab being prescribed in a multidisciplinary committee based on the clinical and analytical findings and the patient{\textquoteright}s refusal to be treated with rituximab. The evaluation at 3 months showed the absence of blisters on the clinical examination. No associated adverse effects were observed. In the following 3 months the patient was administered medication at home in the absence of an anaphylactic reaction and with prior training by the nursing staff of the Hospital Pharmacy Service. After 6 months the medication was suspended with no relapses for 6 months since the last dose. Omalizumab, an anti-IgE monoclonal drug which has a good safety profile with minimum adverse side effects should be considered when there is a contraindication to the use of intravenous therapies (eg, immunoglobulins, rituximab) or prolonged immunosuppressive treatment (eg, methotrexate, azathioprine).}, issn = {2047-9956}, URL = {https://ejhp.bmj.com/content/early/2020/09/12/ejhpharm-2020-002418}, eprint = {https://ejhp.bmj.com/content/early/2020/09/12/ejhpharm-2020-002418.full.pdf}, journal = {European Journal of Hospital Pharmacy} }